Survival after blood transfusion

被引:67
作者
Kamper-Jorgensen, Mads [1 ]
Ahlgren, Martin
Rostgaard, Klaus
Melbye, Mads
Edgren, Gustaf
Nyren, Olof
Reilly, Marie
Norda, Rut
Titlestad, Kjell
Tynell, Elsa
Hjalgrim, Henrik
机构
[1] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark
基金
美国国家卫生研究院;
关键词
D O I
10.1111/j.1537-2995.2008.01881.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Long-term survival of transfusion recipients has rarely been studied. This study examines short- and long-term mortality among transfusion recipients and reports these as absolute rates and rates relative to the general population. Population-based cohort study of transfusion recipients in Denmark and Sweden followed for up to 20 years after their first blood transfusion. Main outcome measure was all-cause mortality. A total of 1,118,261 transfusion recipients were identified, of whom 62.0 percent were aged 65 years or older at the time of their first registered transfusion. Three months after the first transfusion, 84.3 percent of recipients were alive. One-, 5-, and 20-year posttransfusion survival was 73.7, 53.4, and 27.0 percent, respectively. Survival was slightly poorer in men than in women, decreased with increasing age, and was worst for recipients transfused at departments of internal medicine. The first 3 months after the first transfusion, the standardized mortality ratio (SMR) was 17.6 times higher in transfusion recipients than in the general population. One to 4 years after first transfusion, the SMR was 2.1 and even after 17 years the SMR remained significantly 1.3-fold increased. The survival and relative mortality patterns among blood transfusion recipients were characterized with unprecedented detail and precision. Our results are relevant to assessments of the consequences of possible transfusion-transmitted disease as well as for cost-benefit estimation of new blood safety interventions.
引用
收藏
页码:2577 / 2584
页数:8
相关论文
共 28 条
[1]  
Andersen TF, 1999, DAN MED BULL, V46, P263
[2]   Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood [J].
AuBuchon, JP ;
Birkmeyer, JD ;
Busch, MP .
TRANSFUSION, 1997, 37 (01) :45-51
[3]   Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections [J].
Busch, MP ;
Dodd, RY ;
Lackritz, EM ;
AuBuchon, JP ;
Birkmeyer, JD ;
Petersen, LR .
TRANSFUSION, 1997, 37 (10) :1003-1011
[4]   Health care with equity and cost containment [J].
Calltorp, J .
LANCET, 1996, 347 (9001) :587-588
[5]  
*CONS INT EARTH SC, 2007, WHO MORT DAT EL CIT
[6]   The cost-effectiveness of screening the u.S. blood supply for West Nile virus [J].
Custer, B ;
Busch, MP ;
Marfin, AA ;
Petersen, LR .
ANNALS OF INTERNAL MEDICINE, 2005, 143 (07) :486-492
[7]  
Edgren G, 2006, VOX SANG, V91, P316, DOI [10.1111/j.1423-0410.2006.00827.x, 10.1111/j.1423-0410.2006.00817.x]
[8]  
Juel K, 2001, UGESKRIFT LAEGER, V163, P4190
[9]  
Juel K, 1999, DAN MED BULL, V46, P354
[10]   Survival after transfusion as assessed in a large multistate US cohort [J].
Kleinman, S ;
Marshall, D ;
AuBuchon, J ;
Patton, M .
TRANSFUSION, 2004, 44 (03) :386-390